Analyst Price Target is $76.43
▲ +38.36% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Kymera Therapeutics in the last 3 months. The average price target is $76.43, with a high forecast of $80.00 and a low forecast of $67.00. The average price target represents a 38.36% upside from the last price of $55.24.
Current Consensus is
The current consensus among 10 contributing investment analysts is to buy stock in Kymera Therapeutics.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.